

REMARKS

Upon entry of the proposed amendment, claims 3 to 25 will be pending. Claims 1 and 2 have been canceled.

35 U.S.C. 103 (a)


Claims 1, 2, and 11 to 16 and 25 stand rejected as allegedly unpatentable over WO 2001072692, in view of either WO 2001060784 or Silverman, *Organic Chemistry of Drug Design* (1992) pp. 19-23. To expedite prosecution, claims 1 and 2 have been canceled, and claims 11 to 16 and 25 have been amended to depend from claim 3. Accordingly, Applicants respectfully request withdrawal of the rejection.

Double Patenting

Claims 1 to 16 and 25 stand provisionally rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1 to 6 and 16 of co-pending application 10/826,100. Upon indication of allowable subject-matter, Applicants will address the rejection.

Applicants believe that the claims are now in condition for allowance. An early Office Action to that effect is therefore, earnestly solicited.

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000

Respectfully submitted,

Maureen S. Gibbons
Attorney for Applicant
Reg. No. 44,121
Phone: 609-252-3453
Date: May 29, 2007